Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

OWC, GC Group to develop new cannabinoid-based drugs By PBR Staff Writer
One World Cannabis (OWC), a subsidiary of OWC Pharmaceutical Research, has entered into agreement with GC Group to develop new formulations and delivery methods targeting several medical indications.
Contract Research & Services > Contract Services > News
Strategia begins Phase I/IIa trial of anti-cancer agent to treat advanced hematologic malignancies By PBR Staff Writer
Strategia Therapeutics has initiated a Phase I/IIa clinical trial of anti-cancer agent E6201 to treat patients with advanced hematologic malignancies.
Contract Research & Services > Contract Services > News Bristol-Myers Squibb transfers Erbitux rights in North America to Lilly By PBR Staff Writer
Eli Lilly and Bristol-Myers Squibb (BMS) have agreed to transfer rights to Erbitux (cetuximab) in North America, including the US, Canada and Puerto Rico, from BMS to Lilly.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Lexicon, Bristol-Myers select development candidate for neuropathic pain
By PBR Staff Writer
Lexicon Pharmaceuticals and Bristol-Myers Squibb (BMS) have selected a development candidate for neuropathic pain, as part of their neuroscience drug discovery and development alliance.
Contract Research & Services > Contract Services > News
Coherus, Baxter amend collaboration agreement for etanercept biosimilar
By PBR Staff Writer
Coherus BioSciences and Baxter International have made changes to certain financial terms of their collaboration agreement established in August 2013 to develop and commercialize CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets.
Contract Research & Services > Contract Services > News
SELLAS, TrojanTec to develop new TR-1 anti-cancer antennapedia technology
By PBR Staff Writer
Swiss biopharmaceutical firm SELLAS Life Sciences Group has signed an exclusive global collaboration and license agreement with UK-based TrojanTec to develop, market and commercialize new and proprietary TR-1 cancer therapeutic technology and drug.
Contract Research & Services > Contract Services > News
Eyenovia, Senju sign license and development agreement for ophthalmic therapeutics
By PBR Staff Writer
US-based pharmaceutical firm Eyenovia has signed an exclusive license and development agreement with Japanese firm Senju Pharmaceutical, to develop ophthalmic therapeutics based on microdrops technology.
Contract Research & Services > Contract Services > News
Recro completes acquisition of Alkermes' IV/IM Meloxicam and cGMP manufacturing facility
By PBR Staff Writer
Recro Pharma has completed the acquisition of assets from Alkermes and its affiliates including worldwide rights to IV/IM meloxicam, and a contract manufacturing facility, royalty and formulation business.
Contract Research & Services > Contract Services > News
Vetter announces Oliver Albrecht has been appointed Managing Director
Vetter, a leading contract development and manufacturing organization that specializes in aseptic manufacturing, today announced that the company’s Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective April 1, 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.
Contract Research & Services > Contract Services > Press Releases
Pfizer, Merck finalize deal to co-promote lung cancer drug Xalkori
By PBR Staff Writer
US-based Pfizer and German drug maker Merck have finalized a co-promotion agreement that will enable the companies to co-promote Pfizer's anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) for the treatment of non-small cell lung cancer (NSCLC).
Contract Research & Services > Contract Services > News
Depomed acquires US rights to Nucynta franchise for $1.05bn from Janssen
By PBR Staff Writer
Depomed has completed acquisition of the US license rights to the Nucynta franchise from Janssen Pharmaceuticals for $1.05bn.
Contract Research & Services > Contract Services > News
Neurocrine, Mitsubishi Tanabe to develop VMAT2 inhibitor NBI-98854 for movement disorders
By PBR Staff Writer
US-based Neurocrine Biosciences has entered into an exclusive collaboration and licensing agreement with Japanese firm Mitsubishi Tanabe Pharma to develop and commercialize its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets.
Contract Research & Services > Contract Services > News
Merck Serono, MVV to develop potential antimalarial therapy
By PBR Staff Writer
Merck Serono has signed an agreement with Medicines for Malaria Venture (MMV) to secure the rights to MMV's investigational antimalarial compound, DDD107498.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests